Sara Collins, MD
Cardiovascular Disease · Bowie, MDNPI 1023275229
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $51,238 of the $60,870 with a category attached, or 84.2%. 35 manufacturers reported payments, led by Amgen at 48.1% of the total. 2025 is the largest year on record at $42,577, more than ten times the $1,670 reported in 2019. Among cardiovascular disease clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 214 payments — averaging $284.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$29K
- UCB, Inc.$8K
- Eli Lilly$8K
- Pfizer$6K
- Novo Nordisk$4K
- Abbott$2K
- plus $5K from 29 others
Across 53 payments — averaging $7361.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Cleerly, Inc.$251K
- Amgen$83K
- Novartis$28K
- Genentech, Inc.$24K
- Bayer$5K
- Eli Lilly$313
What the payments were for
- Consulting fees$51,23884%
- Travel & lodging$2,4404%
- Food & beverage$7,16112%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 30 | $29,257 |
| UCB, Inc. | 8 | $7,595 |
| Eli Lilly | 20 | $7,542 |
| Pfizer | 15 | $6,347 |
| Novo Nordisk | 13 | $3,820 |
| Abbott | 21 | $1,577 |
| Novartis | 25 | $1,401 |
| Merck | 12 | $1,032 |
| Alnylam Pharmaceuticals Inc. | 8 | $362 |
| AstraZeneca | 11 | $228 |
| Medtronic | 3 | $210 |
| Boston Scientific | 4 | $173 |
| Johnson & Johnson | 7 | $136 |
| Cardiovascular Systems Inc. | 1 | $129 |
| Edwards Lifesciences | 1 | $119 |
| Regeneron Healthcare Solutions, Inc. | 5 | $118 |
| Biotronik Inc. | 1 | $110 |
| E.r. Squibb & Sons, L.L.C. | 5 | $106 |
| Astellas Pharma Global Development | 1 | $91 |
| Esperion Therapeutics, Inc. | 3 | $71 |
| Gilead | 3 | $52 |
| Philips North America LLC | 2 | $48 |
| Heartflow, Inc. | 2 | $45 |
| Amarin Pharma, Inc. | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Boehringer Ingelheim | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $33 |
| Atricure, Inc. | 1 | $28 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Bayer | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Irhythm Technologies, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$6,125
- Confirm Rx$314
- JOT DX$172
- SYMPLICITY G3$155
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$145
- Quadra Assura CRT Defibrillator$141
- Assurity Pacemaker$141
- Zephyr Pacemaker$137
- Coronary Orbital Atherectomy System$129
- CARDIOMEMS$114
- ONPATTRO$112
- Ozempic$109
How this compares
$60,870 in reported general payments places this provider in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 59 | $51,228 |
| Repatha SureclickEvolocumab | 21 | $25,635 |
| EntrestoSacubitril/Valsartan | 23 | $25,601 |
| FarxigaDapagliflozin Propanediol | 27 | $19,201 |
| XareltoRivaroxaban | 11 | $9,437 |
| EdarbiAzilsartan Medoxomil | 11 | $2,696 |
| Rosuvastatin Calcium | 61 | $1,846 |
| Metoprolol Succinate | 74 | $1,311 |
| Atorvastatin Calcium | 125 | $1,179 |
| Ranolazine ErRanolazine | 11 | $1,153 |
| Ezetimibe | 17 | $969 |
| Amlodipine Besylate | 44 | $514 |
| Hydralazine Hcl | 60 | $483 |
| Nebivolol Hcl | 16 | $424 |
| Losartan Potassium | 28 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $6,347 | $51,22859 claims |
| NovartisEntresto | $1,401 | $25,60123 claims |
| AstraZenecaFarxiga | $228 | $19,20127 claims |
| Johnson & JohnsonXarelto | $136 | $9,43711 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $17 | $2,69611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 cardiovascular disease providers in Maryland.
Other cardiovascular disease in Bowie
- Barbara HutchinsonBowie$77K
- Navin KapurBaltimore$1.5M
- Michael BlahaBaltimore$609K
- Sanjay RajagopalanBaltimore$521K
- Allen TaylorN Bethesda$456K
- David GoorayLargo$333K
- Erin MichosBaltimore$257K
- Seth MartinBaltimore$166K
- Erika FellerBaltimore$121K
- Mark HaigneyBethesda$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.